First Business Financial Services Inc. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

First Business Financial Services Inc. grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,806 shares of the medical research company’s stock after purchasing an additional 253 shares during the period. First Business Financial Services Inc.’s holdings in IQVIA were worth $1,927,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. lifted its position in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in shares of IQVIA during the 3rd quarter valued at approximately $57,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $186.04 on Thursday. The stock has a market cap of $32.80 billion, a PE ratio of 24.81, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $261.73. The stock has a fifty day simple moving average of $198.24 and a 200-day simple moving average of $213.66.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. UBS Group reduced their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Truist Financial reissued a “buy” rating and issued a $263.00 price objective (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.